Advanced HCC Treated by Systemic Immunotherapy
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Laurent PharmaceuticalsQC - Montréal
1 programCT Perfusion Parameters for Advanced HCC Treated by Systemic ImmunotherapyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Laurent PharmaceuticalsCT Perfusion Parameters for Advanced HCC Treated by Systemic Immunotherapy
Clinical Trials (1)
Total enrollment: 9 patients across 1 trials
NCT05580809Laurent PharmaceuticalsCT Perfusion Parameters for Advanced HCC Treated by Systemic Immunotherapy
CT Perfusion Parameters for Advanced HCC Treated by Systemic Immunotherapy
Start: Aug 2021Est. completion: Aug 20229 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.